PL3532497T3 - Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji - Google Patents

Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji

Info

Publication number
PL3532497T3
PL3532497T3 PL17865245.9T PL17865245T PL3532497T3 PL 3532497 T3 PL3532497 T3 PL 3532497T3 PL 17865245 T PL17865245 T PL 17865245T PL 3532497 T3 PL3532497 T3 PL 3532497T3
Authority
PL
Poland
Prior art keywords
hemaglutinating
reduce
hinge regions
immunoglobulin hinge
modified immunoglobulin
Prior art date
Application number
PL17865245.9T
Other languages
English (en)
Inventor
Jie Liu
Irving L. Weissman
Ravindra Majeti
Original Assignee
The Board Of Trustees Of The Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Board Of Trustees Of The Leland Stanford Junior University filed Critical The Board Of Trustees Of The Leland Stanford Junior University
Publication of PL3532497T3 publication Critical patent/PL3532497T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PL17865245.9T 2016-10-26 2017-10-26 Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji PL3532497T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662413018P 2016-10-26 2016-10-26
PCT/US2017/058569 WO2018081448A1 (en) 2016-10-26 2017-10-26 Modified immunoglobulin hinge regions to reduce hemagglutination

Publications (1)

Publication Number Publication Date
PL3532497T3 true PL3532497T3 (pl) 2024-11-04

Family

ID=62025462

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17865245.9T PL3532497T3 (pl) 2016-10-26 2017-10-26 Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji

Country Status (5)

Country Link
US (2) US10995152B2 (pl)
EP (1) EP3532497B1 (pl)
ES (1) ES2987333T3 (pl)
PL (1) PL3532497T3 (pl)
WO (1) WO2018081448A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3532497T3 (pl) * 2016-10-26 2024-11-04 The Board Of Trustees Of The Leland Stanford Junior University Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji
WO2019079548A1 (en) 2017-10-18 2019-04-25 Forty Seven, Inc. OVARIAN CANCER THERAPY BASED ON ANTI-CD47 AGENT
CA3191835A1 (en) * 2020-09-28 2022-03-31 Jiin-Tarng WANG Anti-cd47 antibodies and methods of use
CN119505008A (zh) * 2023-08-23 2025-02-25 菲鹏生物股份有限公司 免疫球蛋白及其多聚体

Family Cites Families (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
CN1018817B (zh) 1988-12-17 1992-10-28 中国石油化工总公司石油化工科学研究院 具有提高酸性的交联粘土的制备
US7437305B1 (en) 1999-05-11 2008-10-14 Christopher Angel Kantarjiev Scheduling delivery of products via the internet
US6900292B2 (en) 2001-08-17 2005-05-31 Lee-Hwei K. Sun Fc fusion proteins of human erythropoietin with increased biological activities
US20090000224A1 (en) 2002-02-07 2009-01-01 Bay Industries, Inc. Pultruded door frame
GB0304823D0 (en) 2003-03-03 2003-04-09 Dca Internat Ltd Improvements in and relating to a pen-type injector
US20060204496A1 (en) * 2003-11-28 2006-09-14 Tetsuo Kojima Agonist antibody against heteroreceptor
JP2005296412A (ja) 2004-04-13 2005-10-27 Olympus Corp 内視鏡治療装置
US8840933B2 (en) 2006-05-03 2014-09-23 Warsaw Orthopedic, Inc. Method of treating neuronal injury by administering magnesium chloride and PEG
US8330550B2 (en) 2006-06-23 2012-12-11 Rgb Systems, Inc. Method and apparatus for automatic compensation of video signal losses from transmission over conductors
PL2109622T3 (pl) * 2007-01-03 2017-06-30 Morphotek, Inc. Przeciwciała o wysokim powinowactwie neutralizujące gronkowcową enterotoksynę B
WO2009006520A1 (en) 2007-07-03 2009-01-08 Medimmune, Llc Hinge domain engineering
CA3108119C (en) 2008-01-15 2024-01-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
PT2242512T (pt) 2008-01-15 2016-07-18 Univ Leland Stanford Junior Métodos para manipular a fagocitose mediada por cd47
GB2459509B (en) 2008-04-25 2011-05-11 Goodwin Plc An apparatus for casting and a method of casting
AR074438A1 (es) 2008-12-02 2011-01-19 Pf Medicament Proceso para la modulacion de la actividad antagonista de un anticuerpo monoclonal
US8758750B2 (en) 2009-09-15 2014-06-24 The Board Of Trustees Of The Leland Stanford Junior University Synergistic anti-CD47 therapy for hematologic cancers
JP5837821B2 (ja) 2009-09-24 2015-12-24 中外製薬株式会社 抗体定常領域改変体
SI2506871T1 (sl) 2009-11-30 2016-12-30 Janssen Biotech, Inc. Mutanti Fc protitelesa z odstranjenimi efektorskimi funkcijami
US9276975B2 (en) 2010-03-24 2016-03-01 Thomson Licensing Method and apparatus for monitoring quality of service of network
JP2011216948A (ja) 2010-03-31 2011-10-27 Sony Corp カメラシステム、映像処理装置及びカメラ装置
EP4349868A3 (en) * 2010-05-14 2024-08-28 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
US9183590B2 (en) 2010-07-20 2015-11-10 Neopost Technologies System and method for managing postal accounting data using transient data collectors
GB201014033D0 (en) 2010-08-20 2010-10-06 Ucb Pharma Sa Biological products
EP2646007B1 (en) 2010-12-02 2016-12-21 Neurotech USA, Inc. Cell lines that secrete anti-angiogenic antibody-scaffolds and soluble receptors and uses thereof
EP2694717B1 (en) 2011-04-07 2017-06-28 Cargill, Incorporated Bio-based binders including carbohydrates and a pre-reacted product of an alcohol or polyol and a monomeric or polymeric polycarboxylic acid
AU2012250614B2 (en) * 2011-05-05 2016-02-11 Pharma Cinq, Llc Complement factor B analogs and their uses
PE20141212A1 (es) * 2011-06-22 2014-09-19 Hoffmann La Roche Eliminacion de celulas diana por parte de celulas t citotoxicas especificas de virus utilizando complejos que comprenden mhc de clase 1
JP6460796B2 (ja) * 2012-01-17 2019-01-30 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 高親和性ｓｉｒｐ−アルファ試薬
EA034778B1 (ru) 2012-02-06 2020-03-19 Инхибркс, Инк. Антитела к cd47 и способы их применения
GB201203051D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
DE102012103533A1 (de) 2012-04-20 2013-10-24 Köra-Packmat Maschinenbau GmbH Vorrichtung zum Fördern eines Substrats und System zum Bedrucken eines Substrats
TWI641687B (zh) 2012-05-29 2018-11-21 美商再生元醫藥公司 生產細胞株增強子
KR101910976B1 (ko) 2012-07-16 2018-10-23 삼성전자주식회사 그래핀을 이용한 전계효과 트랜지스터
DE102012213566A1 (de) 2012-08-01 2014-02-06 Robert Bosch Gmbh Verfahren zum Herstellen eines Bondpads zum Thermokompressionsbonden und Bondpad
PL3824905T3 (pl) 2012-08-20 2025-05-05 Fred Hutchinson Cancer Center Sposób i kompozycje do immunoterapii komórkowej
TWI613212B (zh) 2012-10-02 2018-02-01 波克萊拉生物科技股份有限公司 作爲澱粉樣蛋白結合劑之ｇ３ｐ融合蛋白
HRP20192013T1 (hr) 2012-12-17 2020-02-07 Trillium Therapeutics Inc. Liječenje cd47+ oboljelih stanica sa sirp alfa-fc fuzijama
AR094147A1 (es) 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
CA2900256C (en) 2013-02-05 2023-03-21 Kim J. HASENKRUG Cd47 targeted therapies for the treatment of infectious disease
JP2016507555A (ja) * 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法
CN112245586A (zh) * 2013-03-15 2021-01-22 小利兰·斯坦福大学托管委员会 用于实现治疗有效剂量的抗cd47剂的方法
US9657105B2 (en) * 2013-03-15 2017-05-23 City Of Hope CD123-specific chimeric antigen receptor redirected T cells and methods of their use
EP2992089B1 (en) 2013-04-29 2021-09-08 The Board of Trustees of the Leland Stanford Junior University Use of anti-cd47 agents to enhance immunization
US9945870B2 (en) 2013-05-17 2018-04-17 The Board Of Trustees Of The Leland Stanford Junior University Methods for determining responsiveness to an anti-CD47 agent
WO2015022420A1 (en) 2013-08-16 2015-02-19 Medimmune Limited Gip and glp-1 receptor dual-agonists for the treatment of diabetes
EP3046627B1 (en) 2013-09-18 2019-10-23 The Board of Trustees of the Leland Stanford Junior University Modulation of efferocytosis pathways for treatment of atherosclerotic disease
AU2015204766B2 (en) 2014-01-08 2020-08-13 The Board Of Trustees Of The Leland Stanford Junior University Targeted therapy for small cell lung cancer
ES2822561T3 (es) 2014-09-15 2021-05-04 Univ Leland Stanford Junior Direccionamiento a enfermedad por aneurisma modulando las vías de fagocitosis
CN104327187B (zh) * 2014-10-11 2018-06-08 上海兴迪金生物技术有限公司 一种重组人GLP-1-Fc融合蛋白
AU2016209268B2 (en) 2015-01-21 2021-04-29 The Board Of Trustees Of The Leland Stanford Junior University Macrophages eat cancer cells using their own calreticulin as a guide
ES2838925T3 (es) 2015-02-27 2021-07-02 Univ Leland Stanford Junior Terapia de combinación para el tratamiento de la ateroesclerosis
WO2016191305A1 (en) 2015-05-22 2016-12-01 The Board Of Trustees Of The Leland Stanford Junior University Btn3a ectodomain proteins and methods of use
ES2894335T5 (es) 2015-08-26 2024-06-27 Univ Leland Stanford Junior Reducción mejorada de células objetivo con bloqueo de CD47 y un agonista coestimulador inmune
EP3355931B1 (en) * 2015-10-01 2024-06-26 Novo Nordisk A/S Protein conjugates
CN108367073A (zh) 2015-12-11 2018-08-03 小利兰·斯坦福大学托管委员会 以双重靶向cd47和egfr来治疗癌症
KR20190016079A (ko) * 2016-06-07 2019-02-15 마크로제닉스, 인크. 염증성 질환 및 장애의 치료에서 CD32B x CD79B-결합 분자의 사용 방법
PL3532497T3 (pl) * 2016-10-26 2024-11-04 The Board Of Trustees Of The Leland Stanford Junior University Zmodyfikowane regiony zawiasowe immunoglobuliny dla zmniejszania hemaglutynacji

Also Published As

Publication number Publication date
US10995152B2 (en) 2021-05-04
EP3532497A4 (en) 2020-05-13
EP3532497B1 (en) 2024-07-24
US20200048369A1 (en) 2020-02-13
ES2987333T3 (es) 2024-11-14
US11760810B2 (en) 2023-09-19
WO2018081448A1 (en) 2018-05-03
EP3532497A1 (en) 2019-09-04
EP3532497C0 (en) 2024-07-24
WO2018081448A8 (en) 2024-01-04
US20210253740A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
IL263452A (en) Anti-ige antibodies
DK3143042T3 (da) Forbedrede variable immunoglobulindomæner
KR102355950B9 (ko) Tigit에 대한 항체
EP3417133C0 (en) HINGE
EP3481869A4 (en) ANTI-CD73 ANTIBODIES
DK3411410T3 (da) Pd-1-antistoffer
IL263329B (en) Lysine conjugated immunoglobulins
PL3328894T3 (pl) Przeciwciała dla il2rbeta/wspólnego łańcucha gamma
DK3305680T3 (da) Lukke til beholdere
DK3089994T3 (da) Fabs-in-tandem-immunglobulin og anvendelser deraf
KR20180085002A (ko) 인간화된 항-cll-1 항체
EP3530967A4 (en) BIAXIAL HINGE
IL270969A (en) Aggrecan binding immunoglobulins
DK3795591T5 (da) Cys80-konjugerede immunoglobuliner
DK3125942T3 (da) Forstøvning af immunoglobulin
DOS2016000090S (es) Cierre
EP3555382C0 (de) Rigolenhalbelement
PL3698279T3 (pl) Człon zamykający
EP3480482A4 (en) side flange
EP3471668C0 (en) CORK
DK3555383T3 (da) Drænkanal-halvelement
DK3456736T3 (da) Antistofvarianter
EP3532497C0 (en) MODIFIED IMMUNOGLOBULIN HINGE REGIONS TO REDUCE HEMAGGLUTINATION
EP3486414A4 (en) HINGE DEVICE
EP3513304A4 (en) PROVIDING RECOMMENDED CONTENT